COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Identifieur interne : 001A57 ( Main/Curation ); précédent : 001A56; suivant : 001A58COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Auteurs : Dan Zhou [République populaire de Chine] ; Sheng-Ming Dai [République populaire de Chine] ; Qiang Tong [République populaire de Chine]Source :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2020.
Descripteurs français
- KwdFr :
- Activation des lymphocytes (effets des médicaments et des substances chimiques), Betacoronavirus (MeSH), Humains (MeSH), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (traitement médicamenteux), Lymphocytes T (effets des médicaments et des substances chimiques), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Évolution de la maladie (MeSH).
- MESH :
- effets des médicaments et des substances chimiques : Activation des lymphocytes, Lymphocytes T.
- effets indésirables : Hydroxychloroquine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Hydroxychloroquine.
- Betacoronavirus, Humains, Pandémies, Évolution de la maladie.
English descriptors
- KwdEn :
- Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Cytokine Release Syndrome (drug therapy), Cytokine Release Syndrome (prevention & control), Disease Progression (MeSH), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Lymphocyte Activation (drug effects), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Respiratory Distress Syndrome (drug therapy), Respiratory Distress Syndrome (prevention & control), Respiratory Distress Syndrome (virology), SARS-CoV-2 (MeSH), T-Lymphocytes (drug effects).
- MESH :
- chemical , adverse effects : Hydroxychloroquine.
- drug effects : Lymphocyte Activation, T-Lymphocytes.
- drug therapy : Coronavirus Infections, Cytokine Release Syndrome, Pneumonia, Viral, Respiratory Distress Syndrome.
- prevention & control : Cytokine Release Syndrome, Respiratory Distress Syndrome.
- chemical , therapeutic use : Hydroxychloroquine.
- virology : Respiratory Distress Syndrome.
- Betacoronavirus, COVID-19, Disease Progression, Humans, Pandemics, SARS-CoV-2.
Abstract
A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression.
DOI: 10.1093/jac/dkaa114
PubMed: 32196083
PubMed Central: PMC7184499
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A57
Links to Exploration step
pubmed:32196083Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.</title><author><name sortKey="Zhou, Dan" sort="Zhou, Dan" uniqKey="Zhou D" first="Dan" last="Zhou">Dan Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Dai, Sheng Ming" sort="Dai, Sheng Ming" uniqKey="Dai S" first="Sheng-Ming" last="Dai">Sheng-Ming Dai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Tong, Qiang" sort="Tong, Qiang" uniqKey="Tong Q" first="Qiang" last="Tong">Qiang Tong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32196083</idno><idno type="pmid">32196083</idno><idno type="doi">10.1093/jac/dkaa114</idno><idno type="pmc">PMC7184499</idno><idno type="wicri:Area/Main/Corpus">001A57</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A57</idno><idno type="wicri:Area/Main/Curation">001A57</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.</title><author><name sortKey="Zhou, Dan" sort="Zhou, Dan" uniqKey="Zhou D" first="Dan" last="Zhou">Dan Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:affiliation>Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Dai, Sheng Ming" sort="Dai, Sheng Ming" uniqKey="Dai S" first="Sheng-Ming" last="Dai">Sheng-Ming Dai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Tong, Qiang" sort="Tong, Qiang" uniqKey="Tong Q" first="Qiang" last="Tong">Qiang Tong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Cytokine Release Syndrome (drug therapy)</term><term>Cytokine Release Syndrome (prevention & control)</term><term>Disease Progression (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Lymphocyte Activation (drug effects)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Respiratory Distress Syndrome (drug therapy)</term><term>Respiratory Distress Syndrome (prevention & control)</term><term>Respiratory Distress Syndrome (virology)</term><term>SARS-CoV-2 (MeSH)</term><term>T-Lymphocytes (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation des lymphocytes (effets des médicaments et des substances chimiques)</term><term>Betacoronavirus (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Lymphocytes T (effets des médicaments et des substances chimiques)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphocyte Activation</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Cytokine Release Syndrome</term><term>Pneumonia, Viral</term><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Activation des lymphocytes</term><term>Lymphocytes T</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cytokine Release Syndrome</term><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Respiratory Distress Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Disease Progression</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Humains</term><term>Pandémies</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32196083</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>07</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation></Journal><ArticleTitle>COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.</ArticleTitle><Pagination><MedlinePgn>1667-1670</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkaa114</ELocationID><Abstract><AbstractText>A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression.</AbstractText><CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Sheng-Ming</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Antimicrob Chemother. 2020 Jul 1;75(7):2016-2017</RefSource><PMID Version="1">32361760</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId><ArticleId IdType="pii">5810487</ArticleId><ArticleId IdType="doi">10.1093/jac/dkaa114</ArticleId><ArticleId IdType="pmc">PMC7184499</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Exp Med. 2005 Dec 5;202(11):1575-85</Citation><ArticleIdList><ArticleId IdType="pubmed">16330816</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunother Cancer. 2018 Jun 15;6(1):56</Citation><ArticleIdList><ArticleId IdType="pubmed">29907163</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1990 Dec 13;348(6302):600-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2250716</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 1997 Jan;24(1):55-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9002011</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci China Life Sci. 2020 Mar;63(3):457-460</Citation><ArticleIdList><ArticleId IdType="pubmed">32009228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2010 Jan;69(1):20-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19103632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2015 May 1;194(9):4089-93</Citation><ArticleIdList><ArticleId IdType="pubmed">25821216</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Res Ther. 2009;11(4):R109</Citation><ArticleIdList><ArticleId IdType="pubmed">19604357</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Res Ther. 2017 Aug 9;19(1):183</Citation><ArticleIdList><ArticleId IdType="pubmed">28793932</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 1999 Feb;42(2):357-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10025931</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Dec 4;456(7222):658-62</Citation><ArticleIdList><ArticleId IdType="pubmed">18820679</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation><ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1998 Nov 2;17(21):6230-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9799232</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2012 Jul 3;126(1):76-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22626746</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation><ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Apr 15;186(8):4794-804</Citation><ArticleIdList><ArticleId IdType="pubmed">21398612</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2015 Apr 16;202:120-34</Citation><ArticleIdList><ArticleId IdType="pubmed">25445340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2017 Aug;76(8):1476-1480</Citation><ArticleIdList><ArticleId IdType="pubmed">28501799</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2018 Dec;14(12):693-703</Citation><ArticleIdList><ArticleId IdType="pubmed">30401979</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation><ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2017 Mar;44(3):398</Citation><ArticleIdList><ArticleId IdType="pubmed">28250164</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001A57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:32196083
|texte= COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32196083" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |